Open AccessSerum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer
Author(s) -
Yıldız Okuturlar,
Meral Günaldı,
Hakan Koçoğlu,
Mehmet Hurşitoğlu,
Asuman Gedikbaşı,
Didem Acarer,
Özlem Harmankaya,
Abdülbaki Kumbasar
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.235355
Subject(s) - arylesterase , medicine , breast cancer , receiver operating characteristic , gastroenterology , chemotherapy , paraoxonase , cancer , oncology , biology , genotype , biochemistry , oxidative stress , pon1 , gene
The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC.